TrialBreast cancer research and treatment2020

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.

Hiroshi Ishiguro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.